Dogwood Therapeutics, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Dogwood Therapeutics, Inc. (DWTX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $9.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-14
- Dogwood Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $9.19M.
- Dogwood Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-03-31 was $0.00.
- Dogwood Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- Dogwood Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- Dogwood Therapeutics, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.19M 10-Q · filed 2026-08-14 | $9.19M 10-Q · filed 2026-08-14 | $9.19M derived: sum of 3 quarters · filed 2026-08-14 | $9.19M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |